Breast Cancer News and Research

Latest Breast Cancer News and Research

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Huixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to drug therapy, leading to a relapse of the disease.

26 Feb 2010

Massaging advanced cancer patients for 14 minutes can reduce stress: Study

Advanced cancer patients who regularly received massages averaging 14 minutes or more by a partner or family member declined in stress scores over four weeks, according to results of a study reported at the 7th annual conference of the American Psychosocial Oncology Society.

26 Feb 2010

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

Do we need a revision of current recommendations for breast cancer screening? According to a recent prospective multicenter cohort study published in the "Journal of Clinical Oncology", this appears advisable at least for young women carrying an increased risk of breast cancer. The results of the EVA trial confirm once more that magnetic resonance imaging (MRI) is substantially more accurate for early diagnosis of breast cancer than digital mammography or breast ultrasound: MRI is three times more sensitive for breast cancer than digital mammography.

26 Feb 2010

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

Contralateral prophylactic mastectomy (CPM), a preventive procedure to remove the unaffected breast in patients with disease in one breast, may only offer a survival benefit to breast cancer patients age 50 and younger, who have early-stage disease and are estrogen receptor (ER) negative, according to researchers at The University of Texas M. D. Anderson Cancer Center.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Genta initiates new dose-ranging study of tesetaxel drug

Genta Incorporated announced that the Company has initiated a new dose-ranging study of tesetaxel, the Company’s novel oral tubulin inhibitor, using a weekly dosing regimen. Tesetaxel -- a late Phase 2 oncology product -- is the leading oral taxane currently in clinical development.

26 Feb 2010

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

Monash University biomedical scientists have identified a new way to treat castrate resistant cells in prostate cancer sufferers - the most common cancer in Australian men.

25 Feb 2010

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

OncoGenex Pharmaceuticals announced today that it has received written, scientific advice from the European Medicines Agency (EMA) on the company's development plan for OGX-011 (also known as custirsen) for the treatment of men with metastatic castrate-resistant prostate cancer (mCRPC). The input received from the Committee for Medicinal Products for Human Use (CHMP) at the EMA was in overall agreement with OncoGenex's development plan regarding the proposed preclinical studies and both the study designs and analyses for the Phase III trials.

25 Feb 2010

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

In a laboratory study published in the journal Cancer Research, Scott & White Healthcare anatomic pathologist Arundhati Rao, M.D. is a co-investigator looking at the ways in which estrogen can interfere with how chemotherapy does its job in destroying breast cancer cells.

25 Feb 2010

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

25 Feb 2010

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That's the finding of a new study in the latest issue of the New England Journal of Medicine.

25 Feb 2010

Institute of Medicine to be congratulated for calling more resources to fight hypertension

The Institute of Medicine is to be congratulated for sounding the call for more resources to fight hypertension (high blood pressure), the number two preventable cause of death and a leading contributor to heart disease and stroke. Heart disease and stroke are the number one and three overall causes of death of individuals in the United States.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Tower Wound Care Center of Santa Monica and Tower Surgical Center are pleased to announce the grand opening of its new state-of-the-art facilities at St. John’s Medical Plaza in Santa Monica, California.

25 Feb 2010

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 1 study of PEG-SN38 for pediatric cancer patients. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection). The study is designed to find the recommended dose of PEG-SN38 in pediatric patients. The PEG-SN38 compound is currently being evaluated in Phase 2 studies for metastatic colorectal and breast cancer.

24 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

In some states women ages 40 to 49 have less access to mammograms since the U.S. Preventive Services Task Force (USPSTF) released its recommendations to change breast cancer screening guidelines last November, according to a recent survey conducted by the Avon Foundation for Women. The USPSTF recommended changing the current mammography screening guidelines for average risk women to begin biennial screening at age 50 instead of annual mammograms starting at age 40.

24 Feb 2010

Scientists identify key mechanism of drug resistance in breast cancer patients

CANCER RESEARCH UK funded scientists have discovered why some breast cancers are resistant to the commonly used drug tamoxifen, their findings are published in Cancer Research.

24 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

Breast Cancer News and Research

Latest Breast Cancer News and Research

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Massaging advanced cancer patients for 14 minutes can reduce stress: Study

EVA trial: MRI is more accurate for early diagnosis of breast cancer than digital mammography

CPM procedure may only offer survival benefit to breast cancer patients age 50 and younger

New dietary supplement blocks triggering mechanism causing breast cell mutations

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Genta initiates new dose-ranging study of tesetaxel drug

Scientists identify new way to treat castrate resistant cells in prostate cancer patients

OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC

Lab research targets 'estrogen-receptor positive' breast cancer cells; identifies key protein

Signaling molecules may link certain actions of B cells to solid tumor growth: Study

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Institute of Medicine to be congratulated for calling more resources to fight hypertension

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

TWC, TSC announce the grand opening of new facilities at St. John’s Medical Plaza in Santa Monica

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

Scientists identify key mechanism of drug resistance in breast cancer patients

Findings suggest bitter melon extract may help in preventing breast cancer

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Breast Cancer News and Research

Latest Breast Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in